MedTrace Logo

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

NCT01255891 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-12-09

No results posted yet for this study

Summary

To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post radical prostatectomy patients with high risk pathological features for failure. To determine the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and clinical progression rate at 5 years.

Conditions

  • Adenocarcinoma of the Prostate

Interventions

RADIATION

Androgen suppression plus radiation therapy

Adjuvant androgen suppression plus radiation therapy

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    collaborator INDUSTRY

  • Dr. Tamim Niazi

    lead OTHER

Principal Investigators

  • Tamim Niazi, MD · McGill University Department of Oncology

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2023-08-01
Completion
2023-09-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255891 on ClinicalTrials.gov